 |
|
Members of the National Psoriasis Foundation
More Extensive Disease and Better Informed About Treatment Options
Tamar Nijsten, MD;
Tara Rolstad, MBA;
Steven R. Feldman, MD, PhD;
Robert S. Stern, MD
Arch Dermatol. 2005;141:19-26.
Objective Patient advocacy groups such as the National Psoriasis Foundation (NPF) serve as representatives of those affected by disease and provide information about the condition. Our objective was to assess the extent to which NPF members differ from nonmember patients with psoriasis in their knowledge and use of therapies.
Participants Using random-digit dialing, we identified and interviewed patients with psoriasis in the general US population. Randomly selected NPF members were also interviewed.
Main Outcome Measures Multivariate logistic regression models were used to estimate differences (odds ratios and 95% confidence intervals) in demographic and clinical characteristics and in awareness and use of therapies between members and others diagnosed as having psoriasis.
Results Of 601 individuals with psoriasis identified from the general population survey, 185 provided a second interview and were defined as nonmembers. We interviewed 289 randomly selected members of the NPF. Although members were significantly older and wealthier and had more extensive disease, they reported the disease to be significantly less of a burden and were more satisfied with therapy than others affected. Compared with nonmembers, members were significantly more likely to have heard of and used most of the 10 therapies assessed. However, the proportion of respondents who were aware of a therapy and who also used it did not differ between groups.
Conclusion Members of the NPF are better informed and more satisfied with available treatment options than nonmember affected patients.
Author Affiliations: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Drs Nijsten and Stern); National Psoriasis Foundation, Portland, Ore (Ms Rolstad); and Wake Forest University School of Medicine, Winston-Salem, NC (Dr Feldman). Dr Nijsten is now with University Hospital Antwerp, Edegem, Belgium.
RELATED ARTICLES
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Alan Menter, Kenneth Gordon, Wayne Carey, Tiffani Hamilton, Scott Glazer, Ivor Caro, Nicole Li, Wayne Gulliver, and for the Efalizumab Study Group
Arch Dermatol. 2005;141(1):31-38.
ABSTRACT
| FULL TEXT
Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment
Christie L. Carroll, Jan Clarke, Fabian Camacho, Rajesh Balkrishnan, and Steven R. Feldman
Arch Dermatol. 2005;141(1):43-46.
ABSTRACT
| FULL TEXT
Patient Education and Advocacy Groups: A Means to Better Outcomes?
Kenneth B. Gordon
Arch Dermatol. 2005;141(1):80-81.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Balancing the Benefits and Risks of Drug Treatment: A Stated-Preference, Discrete Choice Experiment With Patients With Psoriasis
Seston et al.
Arch Dermatol 2007;143:1175-1179.
ABSTRACT
| FULL TEXT
The (relative) risks of using odds ratios.
Katz
Arch Dermatol 2006;142:761-764.
ABSTRACT
| FULL TEXT
Patient Education and Advocacy Groups: A Means to Better Outcomes?
Gordon
Arch Dermatol 2005;141:80-81.
FULL TEXT
|
